Through understanding of the molecular mechanism, we proposed that NRF2 or associated proteins may serve as biomarkers for lung cancer or NRF2-addicted cancer patients that may benefit from ZVI-NP treatment. This evidence concerns the gene NFE2L2 and lung cancer.